Literature DB >> 11855890

Tumor chemoconversion following surgery, chemotherapy, and normalization of serum tumor markers in a woman with a mixed type germ cell ovarian tumor.

Yehuda Ben David1, Amir Weiss, Lea Shechtman, Eliezer Shalev.   

Abstract

BACKGROUND: Malignant germ cell tumors of the ovary are often curative after conservative surgery and adjuvant chemotherapy. Persistent tumors despite normalization of serum tumor markers may represent retroconversion to benign masses, but this is rare in ovarian tumors without teratoma elements. The management in such cases has not been defined. CASE: A young woman with a stage IIIC mixed germ cell ovarian tumor containing endodermal and dysgerminoma elements and elevated serum tumor markers underwent conservative surgery followed by chemotherapy. Residual tumor persisted on CT despite the normalization of serum tumor markers. The residual tissue was resected and contained benign tissue.
CONCLUSIONS: In cases where masses persist and serum tumor markers normalize, attaining a histological diagnosis, and not chemotherapy, should be considered.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855890     DOI: 10.1006/gyno.2001.6541

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Granulosa theca cell tumor with erythrocytosis in a llama.

Authors:  David E Anderson; C Guillermo Couto; Michael Oglesbee
Journal:  Can Vet J       Date:  2010-10       Impact factor: 1.008

2.  Growing teratoma syndrome of ovary.

Authors:  Roopa Hariprasad; Lalit Kumar; Deepa Janga; Sunesh Kumar; Malini Vijayaraghavan
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

3.  Growing Teratoma Syndrome Secondary to Ovarian Giant Immature Teratoma in an Adolescent Girl: A Case Report and Literature Review.

Authors:  Song Li; Zhenzhen Liu; Chengyong Dong; Fei Long; Qinlong Liu; Deguang Sun; Zhenming Gao; Liming Wang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.